QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 专题：合肥物质科学研究院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib 期刊论文 ANNALS OF PALLIATIVE MEDICINE, 2022, 卷号: 11 作者:  Fan, Ying;  Qin, Jing;  Han, Na;  Lu, Hongyang 收藏  |  浏览/下载：17/0  |  提交时间：2022/12/23 Leptomeningeal metastasis (LM)  cerebrospinal fluid  HER2 exon 20 insertion mutations  poziotinib  case report   The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study 期刊论文 CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021 作者:  Wang, Wenxian;  Gu, Xiaodong;  Wang, Liping;  Pu, Xingxiang;  Feng, Huijing 收藏  |  浏览/下载：27/0  |  提交时间：2022/01/10 Non-small cell lung cancer  PD-L1  Immune checkpoint inhibitor  Immune-related adverse event   Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study 期刊论文 LEUKEMIA, 2020 作者:  Yang, Yong;  Wang, Ying;  Liu, Xin;  He, Xia;  Zhang, Li-Ling 收藏  |  浏览/下载：109/0  |  提交时间：2020/11/30 Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients 期刊论文 CHINESE MEDICAL JOURNAL, 2013, 卷号: 126 - 收藏  |  浏览/下载：5/0  |  提交时间：2020/10/26 PHASE-III  DOCETAXEL  CHEMOTHERAPY